At a glance
- Originator Duke University Medical Center; GlaxoSmithKline
- Class Antineoplastics; Benzene derivatives; Carboxylic acids; Small molecules
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 03 Oct 2001 No-Development-Reported for Breast cancer in USA (Unknown route)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 22 Aug 1997 Preclinical development for Breast cancer in USA (Unknown route)